Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19095861 | COMPOSITIONS, KITS, AND METHODS FOR IN VITRO TRANSCRIPTION | March 2025 | October 2025 | Allow | 7 | 0 | 1 | Yes | No |
| 18879948 | NOVEL PHOSPHOENOLPYRUVATE CARBOXYLASE VARIANT AND METHOD FOR PRODUCING 5’-INOSINIC ACID USING SAME | December 2024 | June 2025 | Allow | 6 | 0 | 0 | Yes | No |
| 18879104 | MODIFIED MICROORGANISM OF GENUS CORYNEBACTERIUM PRODUCING L-GLUTAMIC ACID AND METHOD FOR PRODUCING L-GLUTAMIC ACID USING SAME | December 2024 | August 2025 | Allow | 8 | 0 | 1 | Yes | No |
| 18984347 | RECOMBINANT HUMANIZED TYPE III COLLAGEN MICROSPHERE WITH INNOVATIVE SPATIAL STRUCTURE, AND DESIGN, PREPARATION PROCESS AND USETHEREOF | December 2024 | July 2025 | Allow | 7 | 1 | 1 | Yes | No |
| 18723639 | NOVEL PROMOTER VARIANT FOR CONSTITUTIVE EXPRESSION AND USES THEREOF | June 2024 | April 2025 | Allow | 10 | 0 | 1 | Yes | No |
| 18721879 | ZAVARZINIA COMPRANSORIS CAPABLE OF DEGRADING ORGANOPHOSPHORUS FLAME RETARDANT AND USE THEREOF | June 2024 | June 2025 | Allow | 12 | 0 | 0 | Yes | No |
| 18731571 | IMMOBILIZED ENZYMES FOR BIOELECTROCATALYSIS | June 2024 | July 2025 | Allow | 13 | 1 | 1 | Yes | No |
| 18648034 | PROCESSES AND SYSTEMS TO PRODUCE RENEWABLE ENERGY AND FIBER FROM CELLULOSE-RICH WASTE MATERIALS | April 2024 | April 2025 | Allow | 11 | 1 | 1 | No | No |
| 18626782 | ENGINEERING STRAIN PRODUCING CORDYCEPIN AND ITS DERIVATIVE 3'-DEOXYINOSINE, ITS PREPARATION METHOD AND APPLICATION | April 2024 | March 2025 | Allow | 11 | 1 | 1 | Yes | No |
| 18614748 | Construction Method and Applications of Glycosyltransferase BS-YjiC Mutant | March 2024 | September 2024 | Allow | 5 | 0 | 2 | Yes | No |
| 18613291 | GENETICALLY MODIFIED BACILLUS SUBTILIS STRAIN, OPTIMIZED VECTORS, AND USES THEREOF | March 2024 | December 2025 | Allow | 20 | 0 | 1 | Yes | No |
| 18612615 | METHODS AND COMPOSITIONS FOR THE ENZYMATIC PRODUCTION OF PSEUDOURIDINE TRIPHOSPHATE | March 2024 | January 2025 | Allow | 10 | 1 | 1 | Yes | No |
| 18433739 | METHOD FOR THE INCORPORATION OF FORMALDEHYDE INTO BIOMASS | February 2024 | March 2026 | Allow | 25 | 1 | 1 | Yes | No |
| 18421303 | HETEROLOGOUS PRODUCTION OF LEUPEPTIN IN PROTEASE INHIBITORS AND ANALOGS THEREOF | January 2024 | October 2025 | Abandon | 21 | 0 | 1 | No | No |
| 18392655 | ACETYL-COA PRODUCING ENZYMES IN YEAST | December 2023 | January 2026 | Allow | 25 | 1 | 1 | Yes | No |
| 18392370 | LIPASE VARIANTS AND COMPOSITIONS COMPRISING SURFACTANT AND LIPASE VARIANT | December 2023 | December 2025 | Allow | 24 | 1 | 1 | Yes | No |
| 18525555 | FUSION PROTEINS FOR BASE EDITING | November 2023 | July 2025 | Abandon | 19 | 0 | 1 | No | No |
| 18506836 | METHODS AND COMPOSITIONS FOR PROMOTING NON-NATURAL AMINO ACID-CONTAINING PROTEIN PRODUCTION | November 2023 | November 2025 | Allow | 24 | 1 | 1 | Yes | No |
| 18500785 | MODIFIED ARCHAEAL FAMILY B POLYMERASES | November 2023 | September 2025 | Allow | 22 | 1 | 1 | Yes | No |
| 18497736 | MICROORGANISM FOR PRODUCING HUMAN MILK OLIGOSACCHARIDE | October 2023 | March 2026 | Allow | 28 | 1 | 1 | Yes | No |
| 18492264 | GALACTOSE TO TAGATOSE ISOMERIZATION AT MODERATE TEMPERATURES WITH HIGH CONVERSION AND PRODUCTIVITY | October 2023 | October 2025 | Allow | 24 | 1 | 1 | Yes | No |
| 18482421 | POLYPEPTIDE MONOLITHS | October 2023 | November 2025 | Abandon | 25 | 1 | 1 | No | No |
| 18473416 | KERATINASE COMPOSITION | September 2023 | July 2025 | Allow | 21 | 1 | 1 | Yes | No |
| 18473809 | ENGINEERED ARYL SULFATE-DEPENDENT ENZYMES | September 2023 | September 2025 | Abandon | 24 | 1 | 1 | No | No |
| 18469527 | D-AMINO ACID OXIDASE MUTANTS AND USES THEREOF IN PREPARING L-GLUFOSINATE | September 2023 | April 2024 | Allow | 7 | 0 | 1 | Yes | No |
| 18456663 | CAS9 VARIANTS AND METHODS OF USE | August 2023 | August 2025 | Allow | 24 | 1 | 1 | Yes | No |
| 18456894 | SECONDARY ACETATE FERMENTATION | August 2023 | May 2025 | Abandon | 21 | 0 | 1 | No | No |
| 18454874 | METHOD FOR PRODUCING SEDOHEPTULOSE | August 2023 | March 2025 | Allow | 19 | 3 | 0 | Yes | No |
| 18225213 | ENGINEERED ARYL SULFATE-DEPENDENT ENZYMES | July 2023 | November 2025 | Abandon | 27 | 1 | 1 | No | No |
| 18354262 | GADUSOL DERIVATIVE PRODUCTION IN BACTERIA | July 2023 | April 2025 | Allow | 21 | 0 | 1 | Yes | No |
| 18346715 | MICROORGANISMS AND METHODS FOR ENHANCING THE AVAILABILITY OF REDUCING EQUIVALENTS IN THE PRESENCE OF METHANOL, AND FOR PRODUCING 1,4-BUTANEDIOL RELATED THERETO | July 2023 | February 2026 | Allow | 32 | 2 | 1 | Yes | No |
| 18343633 | METHODS FOR CO-ACTIVATING IN VITRO NON-STANDARD AMINO ACID (nsAA) INCORPORATION AND GLYCOSYLATION IN CRUDE CELL LYSATES | June 2023 | January 2026 | Allow | 31 | 1 | 1 | No | No |
| 18337172 | Lipase Variants and Polynucleotides Encoding Same | June 2023 | October 2025 | Allow | 28 | 2 | 1 | Yes | No |
| 18206319 | METHODS AND COMPOSITIONS FOR THE ENZYMATIC PRODUCTION OF PSEUDOURIDINE TRIPHOSPHATE | June 2023 | February 2024 | Allow | 9 | 1 | 1 | Yes | No |
| 18298995 | NOVEL ENZYMES AND SYSTEMS FOR SYNTHESIZING DNA | April 2023 | February 2025 | Allow | 22 | 0 | 1 | Yes | No |
| 18187984 | Strain Producing D-allulose 3-epimerase and Application thereof | March 2023 | February 2024 | Allow | 11 | 1 | 1 | Yes | No |
| 18180828 | MAMMALIAN CELL CULTURE | March 2023 | August 2023 | Allow | 5 | 1 | 0 | Yes | No |
| 18178505 | Random Heteropolymers Preserve Protein Function in Foreign Environments | March 2023 | January 2025 | Allow | 22 | 1 | 1 | Yes | No |
| 18160112 | Compositions Of Engineered Human Arginases And Methods For Treating Cancer | January 2023 | February 2025 | Abandon | 25 | 0 | 1 | No | No |
| 18155002 | HIGH-PURITY STEVIOL GLYCOSIDES | January 2023 | February 2026 | Allow | 37 | 2 | 1 | No | No |
| 18096933 | ENGINEERED ARYL SULFATE-DEPENDENT ENZYMES | January 2023 | March 2026 | Abandon | 38 | 0 | 1 | No | No |
| 18152992 | STABILIZED CELLULASE VARIANTS | January 2023 | April 2025 | Allow | 27 | 1 | 1 | Yes | No |
| 18150496 | CARRIER PROTEIN SUBJECTED TO SITE-DIRECTED MUTATION AND USE THEREOF IN PREPARATION OF VACCINE | January 2023 | August 2025 | Allow | 31 | 0 | 1 | Yes | No |
| 18149941 | ENGINEERED BIOCATALYSTS FOR THE SYNTHESIS OF GAMMA-HYDROXY AMINO ACIDS | January 2023 | December 2024 | Allow | 23 | 0 | 1 | Yes | No |
| 18004043 | RENIN-BASED ANALYSIS OF HEPCIDIN | December 2022 | January 2026 | Abandon | 36 | 0 | 1 | No | No |
| 18012573 | MHC MULTIMER EXPRESSION CONSTRUCTS AND USES THEREOF | December 2022 | January 2026 | Abandon | 37 | 0 | 1 | No | No |
| 18072710 | A METHOD FOR REDUCING ODOR IN REMEDIATION OF PESTICIDE CHEMICAL CONTAMINATED SOIL | December 2022 | January 2024 | Allow | 14 | 1 | 1 | Yes | No |
| 18059581 | POLYPEPTIDE AND METHOD OF PRODUCING IMP USING THE SAME | November 2022 | December 2024 | Allow | 24 | 1 | 0 | Yes | No |
| 17998211 | METHOD FOR EFFICIENTLY PRODUCING L-HOMOPHENYLALANINE AND STRAIN PRODUCING L-HOMOPHENYLALANINE | November 2022 | September 2025 | Allow | 35 | 0 | 1 | Yes | No |
| 18053198 | VLP FOR THE TREATMENT OF A LYSOSOMAL STORAGE DISEASE | November 2022 | December 2024 | Abandon | 25 | 0 | 1 | No | No |
| 18053151 | FORMULATIONS COMPRISING RECOMBINANT ACID ALPHA-GLUCOSIDASE | November 2022 | September 2025 | Allow | 34 | 2 | 1 | Yes | No |
| 18049758 | ENGINEERED KETOREDUCTASE POLYPEPTIDES | October 2022 | March 2025 | Allow | 29 | 1 | 1 | No | No |
| 17800484 | METHOD FOR THE INCORPORATION OF FORMALDEHYDE INTO BIOMASS | October 2022 | November 2023 | Allow | 15 | 1 | 1 | Yes | No |
| 17995360 | METHODS AND COMPOSITIONS FOR THE PRODUCTION OF XYLITOL FROM XYLOSE UTILIZING DYNAMIC METABOLIC CONTROL | October 2022 | February 2026 | Allow | 40 | 3 | 1 | Yes | No |
| 17936598 | USES AND METHODS FOR SULFATING A SUBSTRATE WITH A MUTATED ARYLSULFOTRANSFERASE | September 2022 | May 2025 | Abandon | 31 | 1 | 1 | No | No |
| 17934914 | DEGRADABLE CLOSTRIDIAL TOXINS | September 2022 | October 2024 | Abandon | 25 | 0 | 1 | No | No |
| 17934848 | ANTHELMINTIC COMPOSITIONS AND METHODS | September 2022 | November 2025 | Allow | 38 | 3 | 1 | Yes | No |
| 17931351 | Method For Selection Of High M6P Recombinant Proteins | September 2022 | March 2026 | Allow | 42 | 3 | 1 | Yes | No |
| 17930447 | GUIDE RNA COMBINATIONS AND METHODS OF USE | September 2022 | August 2024 | Allow | 23 | 0 | 1 | Yes | No |
| 17929074 | METHODS FOR TREATING OR PREVENTING TISSUE ADHESIONS | September 2022 | May 2025 | Abandon | 32 | 1 | 1 | No | No |
| 17822823 | ENGINEERED KERATINASES DERIVED FROM BACILLUS CEREUS AND ENHANCED METHODS FOR BIODEGRADING FEATHERS AND OTHER KERATIN-CONTAINING MATERIALS | August 2022 | September 2024 | Allow | 25 | 1 | 2 | Yes | No |
| 17894932 | ENGINEERED ARYL SULFATE-DEPENDENT ENZYMES | August 2022 | June 2023 | Allow | 9 | 1 | 1 | Yes | No |
| 17894929 | ENGINEERED ARYL SULFATE-DEPENDENT ENZYMES | August 2022 | June 2023 | Allow | 9 | 1 | 1 | Yes | No |
| 17894933 | ENGINEERED ARYL SULFATE-DEPENDENT ENZYMES | August 2022 | May 2023 | Allow | 9 | 1 | 1 | Yes | No |
| 17889397 | METHOD FOR PRODUCING L-THEANINE VIA FERMENTATION BY A GENETICALLY ENGINEERED BACTERIUM AND THE APPLICATION THEREOF | August 2022 | April 2024 | Allow | 20 | 0 | 0 | Yes | No |
| 17818919 | Mutant Aminoacyl tRNA Synthetase | August 2022 | July 2025 | Allow | 35 | 1 | 1 | Yes | No |
| 17884269 | MICROBIAL APPROACH FOR THE PRODUCTION OF LONG CHAIN COMPOUNDS | August 2022 | January 2025 | Allow | 30 | 1 | 1 | Yes | No |
| 17880715 | Removing Polyphenol Contaminants from Feedstock-based Polyphenols | August 2022 | September 2024 | Abandon | 25 | 0 | 1 | No | No |
| 17871025 | GLYCOSYL HYDROLASE ENZYMES IN HIGH TEMPERATURE INDUSTRIAL PROCESSES | July 2022 | October 2024 | Allow | 27 | 1 | 1 | Yes | No |
| 17813400 | Ribosome-Mediated Incorporation of Peptides and Peptidomimetics | July 2022 | December 2024 | Allow | 29 | 1 | 1 | Yes | No |
| 17813240 | RECOMBINANT MICROORGANISMS AND USES THEREFOR | July 2022 | October 2024 | Allow | 27 | 1 | 1 | Yes | No |
| 17812636 | 3-HYDROXYBUTYRYL-COA DEHYDROGENASE VARIANTS AND METHODS OF USE | July 2022 | September 2024 | Allow | 26 | 1 | 1 | Yes | No |
| 17811325 | LYSIN POLYPEPTIDES ACTIVE AGAINST GRAM-NEGATIVE BACTERIA | July 2022 | December 2025 | Abandon | 41 | 3 | 1 | Yes | No |
| 17850103 | STABLE PROTEASE VARIANTS | June 2022 | February 2026 | Allow | 43 | 0 | 1 | Yes | No |
| 17833539 | POLYPEPTIDE AND METHOD OF PRODUCING IMP USING THE SAME | June 2022 | April 2023 | Allow | 10 | 1 | 1 | Yes | No |
| 17752338 | GENE PROMOTERS FOR USE IN PROKARYOTIC CELLS | May 2022 | May 2024 | Abandon | 24 | 0 | 1 | No | No |
| 17751066 | VARIANT OF NITROUS OXIDE REDUCTASE PROTEIN AND METHOD OF REDUCING CONCENTRATION OF NITROUS OXIDE IN SAMPLE | May 2022 | June 2024 | Allow | 25 | 1 | 1 | Yes | No |
| 17749252 | USE OF LYSIN TO RESTORE/AUGMENT ANTIBACTERIAL ACTIVITY IN THE PRESENCE OF PULMONARY SURFACTANT OF ANTIBIOTICS INHIBITED THEREBY | May 2022 | July 2024 | Allow | 26 | 1 | 1 | Yes | No |
| 17661288 | Nucleic Acid Systems That Enable Bacteria to Specifically Target Solid Tumors via Glucose-Dependent Viability | April 2022 | April 2024 | Allow | 24 | 1 | 1 | No | No |
| 17723284 | NON-RADIOACTIVE CYTOTOXICITY ASSAYS | April 2022 | September 2024 | Allow | 29 | 1 | 1 | Yes | No |
| 17720027 | FLAVONOID AND ANTHOCYANIN BIOPRODUCTION USING MICROORGANISM HOSTS | April 2022 | September 2024 | Allow | 29 | 2 | 1 | Yes | No |
| 17716253 | MODIFIED CASPASE-9 POLYPEPTIDES AND METHODS OF USE THEREOF | April 2022 | May 2024 | Allow | 26 | 1 | 1 | Yes | No |
| 17704593 | Neurotransmitters and Methods of Making the Same | March 2022 | January 2024 | Abandon | 22 | 1 | 1 | No | No |
| 17704317 | VARIANT CAS12 PROTEINS WITH IMPROVED DNA CLEAVAGE SELECTIVITY AND METHODS OF USE | March 2022 | August 2024 | Allow | 29 | 0 | 2 | Yes | No |
| 17761215 | GENETICALLY ENGINEERED STRAIN WITH HIGH YIELD OF L-VALINE AND METHOD FOR PRODUCING L-VALINE BY FERMENTATION | March 2022 | July 2023 | Allow | 16 | 1 | 1 | Yes | No |
| 17642592 | COMPOSITIONS AND METHODS RELATED TO FUNGAL HYPOXIA RESPONSIVE MORPHOLOGY FACTOR A (HRMA) AND BIOFILM ARCHITECTURE FACTOR (BAF) PROTEINS | March 2022 | October 2023 | Allow | 19 | 1 | 1 | Yes | No |
| 17641598 | METHODS AND COMPOSITIONS FOR CELL AND TISSUE REJUVENATION | March 2022 | February 2026 | Allow | 47 | 1 | 1 | Yes | No |
| 17690886 | COMBINATION CHEMOTHERAPY FOR THE TREATMENT OF CANCER | March 2022 | September 2024 | Allow | 30 | 1 | 2 | Yes | No |
| 17641319 | BIOTIN SYNTHASES FOR EFFICIENT PRODUCTION OF BIOTIN | March 2022 | September 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17688024 | ANTI-AGING COMPOSITION AND USE THEREOF FOR PREVENTING AGING | March 2022 | February 2024 | Allow | 23 | 1 | 1 | Yes | No |
| 17680766 | Neurotransmitters and Methods of Making the Same | February 2022 | November 2023 | Abandon | 21 | 0 | 1 | No | No |
| 17678834 | Productivity and Bioproduct Formation in Phototropin Knock/Out Mutants in Microalgae | February 2022 | July 2024 | Allow | 29 | 1 | 1 | Yes | No |
| 17637338 | METHOD FOR SAFELY PRODUCING BOTULINUM NEUROTOXIN | February 2022 | August 2024 | Allow | 30 | 1 | 0 | No | No |
| 17590560 | COMPOSITIONS AND METHODS FOR IN VIVO EXCISION OF HIV-1 PROVIRAL DNA | February 2022 | August 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17630987 | METHOD FOR ANTIBIOTIC SUSCEPTIBILITY TESTING OF BLOOD SAMPLES | January 2022 | February 2026 | Abandon | 48 | 1 | 1 | No | No |
| 17586649 | METHOD FOR PRODUCING ANHYDROUS GALACTOSE DERIVED FROM SEAWEED | January 2022 | March 2024 | Abandon | 25 | 1 | 1 | No | No |
| 17630476 | MODIFIED FILAMENTOUS FUNGAL HOST CELL | January 2022 | September 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17584315 | MOLECULAR GLUE SCREENING ASSAYS AND METHODS FOR PRACTICING SAME | January 2022 | June 2024 | Allow | 29 | 1 | 1 | Yes | No |
| 17627233 | PROTEIN PRODUCTION METHOD AND CELL-FREE PROTEIN SYNTHESIS KIT | January 2022 | December 2025 | Allow | 47 | 1 | 1 | Yes | No |
| 17574742 | Tethering Cysteine Residues Using Cyclic Disulfides | January 2022 | January 2024 | Allow | 24 | 1 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner CHOWDHURY, IQBAL HOSSAIN.
With a 100.0% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 35.3% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner CHOWDHURY, IQBAL HOSSAIN works in Art Unit 1656 and has examined 507 patent applications in our dataset. With an allowance rate of 83.8%, this examiner has an above-average tendency to allow applications. Applications typically reach final disposition in approximately 31 months.
Examiner CHOWDHURY, IQBAL HOSSAIN's allowance rate of 83.8% places them in the 58% percentile among all USPTO examiners. This examiner has an above-average tendency to allow applications.
On average, applications examined by CHOWDHURY, IQBAL HOSSAIN receive 1.65 office actions before reaching final disposition. This places the examiner in the 33% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by CHOWDHURY, IQBAL HOSSAIN is 31 months. This places the examiner in the 54% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.
Conducting an examiner interview provides a +41.4% benefit to allowance rate for applications examined by CHOWDHURY, IQBAL HOSSAIN. This interview benefit is in the 88% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 35.5% of applications are subsequently allowed. This success rate is in the 80% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 43.4% of cases where such amendments are filed. This entry rate is in the 66% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 133.3% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 85% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.
This examiner withdraws rejections or reopens prosecution in 88.9% of appeals filed. This is in the 82% percentile among all examiners. Of these withdrawals, 75.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 69.1% are granted (fully or in part). This grant rate is in the 76% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 12.2% of allowed cases (in the 95% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.5% of allowed cases (in the 55% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.